Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 801–900 of 1,008
Spatially Fractionated Radiotherapy in the Era of Immunotherapy
McMillan, M. T., Khan, A. J., Powell, S. N., Humm, J. L., Deasy, J. O., & Haimovitz‐Friedman, A. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2024.04.002 · Cited by 47
von Reibnitz, D., Chaft, J. E., Wu, A. J.-C., Samstein, R. M., Hellmann, M. D., Plodkowski, A. J., Zhang, Z., Shi, W., Dick-Godfrey, R., Panchoo, K., et al. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.05.001 · Cited by 45
Pirker, R., & Filipits, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.016 · Cited by 45
Toxicity of radiation and immunotherapy combinations
Verma, V., Cushman, T. R., Tang, C. Z., & Welsh, J. W. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.003 · Cited by 43
Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
Perrotta, F., Rocco, D., Vitiello, F., Palma, R. D., Guerra, G., Luca, A. D., Navani, N., & Bianco, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092258 · Cited by 45
Hörner‐Rieber, J., Bernhardt, D., Blanck, O., Duma, M. N., Eich, H. T., Gerum, S., Gkika, E., Hass, P., Henkenberens, C., Herold, H., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.024 · Cited by 48
Krummel, D. P., Nasti, T. H., Izar, B., Press, R. H., Xu, M., Lowder, L., Kallay, L. M., Rupji, M., Rosen, H., Su, J., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.043 · Cited by 43
Gjyshi, O., Xu, T., Elhammali, A. E., Boyce-Fappiano, D. R., Chun, S. G., Gandhi, S. J., Lee, P. P., Chen, A. B., Lin, S. H., Chang, J. Y., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.013 · Cited by 48
Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review
Sabbagh, R. E., Azar, N. S., Eid, A. A., & Azar, S. T. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s261433 · Cited by 48
Tsukita, Y., Yamamoto, T., Mayahara, H., Hata, A., Takeda, Y., Nakayama, H., Tanaka, S., Uchida, J., Usui, K., Toyoda, T., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.05.016 · Cited by 48
Zhu, L., Yu, X., Wang, L., Liu, J., Qu, Z., Zhang, H., Li, L., Chen, J., & Zhou, Q. (2021) · Oncogenesis · doi:10.1038/s41389-021-00335-w · Cited by 46
Yang, F., Zhang, J., Liu, Z., Xia, W., Zhang, R., Wei, H., Feng, J., Zhao, X., Jian, J., Gao, X., et al. (2021) · European Radiology · doi:10.1007/s00330-021-08277-y · Cited by 45
Durvalumab in Stage III Non–Small-Cell Lung Cancer
Copur, M. D., Gauchan, D., & Ramaekers, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1716426 · Cited by 43
Hasegawa, T., Ozaki, Y., Inoue, T., Watanabe, Y., Fukuhara, M., Yamaura, T., Muto, S., Okabe, N., Higuchi, M., Shio, Y., et al. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2245-y · Cited by 42
Wang, C., Cui, A., Bukenya, M., Aung, A., Pradhan, D., Whittaker, C. A., Agarwal, Y., Thomas, A., Liang, S., Amlashi, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110021 · Cited by 48
Lu, X., Wang, J., Zhang, T., Zhou, Z., Deng, L., Wang, X., Wang, W., Liu, W., Tang, W., Wang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.918787 · Cited by 47
Véra, P., Thureau, S., Tinier, F. L., Chaumet‐Riffaud, P., Hapdey, S., Gauthier, H. K., Martin, E., Berriolo-Riedinger, A., Pourel, N., Broglia, J. M., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00320-6 · Cited by 42
New therapeutic options opened by the molecular classification of gastric cancer
Chivu‐Economescu, M., Matei, L., Necula, L. G., Dragu, D., Bleoţu, C., & Diaconu, C. C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i18.1942 · Cited by 56
Augmenting the synergies of chemotherapy and immunotherapy through drug delivery
Kim, J., Manspeaker, M. P., & Thomas, S. N. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.02.012 · Cited by 42
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Mhanna, L., Guibert, N. M., Milia, J., & Mazières, J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0652-3 · Cited by 44
Choe, E., Cha, Y. J., Kim, J. H., Pyo, K., Hong, M. H., Park, S. Y., Shim, H. S., Jung, I., Lee, C. Y., Cho, B. C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.027 · Cited by 45
Self-citationDeterminants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
Horinouchi, H., Atagi, S., Oizumi, S., Ohashi, K., Kato, T., Kozuki, T., Seike, M., Sone, T., Sobue, T., Tokito, T., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3306 · Cited by 45
Self-citationPolymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8+ T Cells
Zhang, J., Zhang, L., Yang, Y., Liu, Q., Ma, H., Huang, A., Zhao, Y., Xia, Z., Liu, T., & Wu, G. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.038 · Cited by 53
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 45
Wrona, A., Dziadziuszko, R., & Jassem, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-552 · Cited by 47
Shi, Y., Liu, X., Liu, J., Zhang, D., Liu, X., Yuan, Y., Zhou, Q., Gao, X., Chen, M., Xu, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-710 · Cited by 52
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 47
Jin, W. J., Erbe, A. K., Schwarz, C. N., Jaquish, A. A., Anderson, B. R., Sriramaneni, R. N., Jagodinsky, J. C., Bates, A. M., Clark, P. A., Le, T. Q. H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591139 · Cited by 42
Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy
Xuan, L., Bai, C., Ju, Z., Luo, J., Guan, H., Zhou, P., & Huang, R. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.003 · Cited by 44
Oyoshi, H., Du, J., Sakai, S. A., Yamashita, R., Okumura, M., Motegi, A., Hojo, H., Nakamura, M., Hirata, H., Sunakawa, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9069 · Cited by 51
Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy
Wang, X., Zhang, H., XinZhang, & Liu, Y. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00628-3 · Cited by 49
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Strati, A. D., Adamopoulos, C., Kotsantis, I., Psyrri, A. K., Lianidou, E. S., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031235 · Cited by 51
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer
Yeh, J., Marrone, K. A., & Forde, P. M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.109 · Cited by 42
McCall, N. S., Dicker, A. P., & Lü, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3269 · Cited by 43
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
Miura, Y., & Sunaga, N. (2018) · Cancers · doi:10.3390/cancers10080245 · Cited by 41
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Carmichael, J. A., Mak, D. W.-S., & O'Brien, M. E. R. (2018) · Cancers · doi:10.3390/cancers10070236 · Cited by 45
Liu, S., Huang, W., Yeh, H., Ko, C.-C., Shieh, H.-R., Hung, C., Chen, T.-Y., & Chen, Y.-J. (2019) · Cancers · doi:10.3390/cancers11040580 · Cited by 44
Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
Zhong, H., Zhou, J., Xu, D., & Zeng, X. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13346 · Cited by 43
The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients
Ismail, R. K., Schramel, F. M. N. H., van Dartel, M., Hilarius, D. L., de Boer, A., Wouters, M. W. J. M., & Smit, H. J. M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.011 · Cited by 43
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Lurain, K. A., Ramaswami, R., Yarchoan, R., & Uldrick, T. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00525-y · Cited by 43
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
Marcus, D., Lieverse, R. I. Y., Klein, C., Abdollahi, A., Lambin, P., Dubois, L. J., & Yaromina, A. (2021) · Cancers · doi:10.3390/cancers13061468 · Cited by 45
Akamatsu, H., Murakami, H., Harada, H., Shimizu, J., Hayashi, H., Daga, H., Hasegawa, Y., Kim, Y. H., Kato, T., Tokunaga, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.019 · Cited by 42
Self-citationVaes, R. D. W., Reynders, K., Sprooten, J., Nevola, K. T., Rouschop, K. M. A., Vooijs, M., Garg, A. D., Lambrecht, M. L. F., Hendriks, L. E. L., Ručević, M., et al. (2021) · Cancers · doi:10.3390/cancers13246259 · Cited by 42
Jang, J. Y., Kim, S. S., Song, S. Y., Kim, Y. J., Kim, S.-W., & Choi, E. K. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01930-2 · Cited by 41
Self-citationThe Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 57
EGFR-Targeted Therapies: A Literature Review
Sha, C., & Lee, P. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216391 · Cited by 46
Management of Brain Metastases in the New Era of Checkpoint Inhibition
Lauko, A. J., Thapa, B., Venur, V. A., & Ahluwalia, M. S. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0877-8 · Cited by 42
Gong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 42
Mauclet, C., Duplaquet, F., Pirard, L., Rondelet, B., Dupont, M., Pop, C. S., Borght, T. V., Remmelink, M., D’Haene, N., Lambin, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.006 · Cited by 40
Kokowski, K., Stangl, S., Seier, S., Hildebrandt, M., Vaupel, P. W., & Multhoff, G. (2019) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01434-9 · Cited by 41
Yang, C., Mi, X., Su, H., Yang, J., Gu, Y. Y., Zhang, L., Sun, W., Liang, X., & Zhang, C. (2019) · Biomaterials Science · doi:10.1039/c8bm01492b · Cited by 41
Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
Inao, T., Kotani, H., Iida, Y., Kartika, I. D., Okimoto, T., Tanino, R., Shiba, E., & Harada, M. (2019) · Cancer Science · doi:10.1111/cas.14116 · Cited by 45
Tsimafeyeu, I. V., Имянитов, Е. Н., Эдуардовна, З. Л., Раскин, Г. А., Повилайтите, П. Е., Савелов, Н. А., Kharitonova, E., Rumyantsev, А. А., Pugach, I. M., Andreeva, Y. Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60950-2 · Cited by 45
Landman, Y., Jacobi, O., Kurman, N., Yariv, O., Peretz, I., Rotem, O., Dudnik, E., Zer, A., & Allen, A. M. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1959979 · Cited by 40
Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Yang, W., Lei, C., Song, S., Jing, W., Jin, C., Gong, S., Tian, H., & Guo, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02299-8 · Cited by 43
McCall, N. S., McGinnis, H. S., Janopaul-Naylor, J. R., Kesarwala, A. H., Tian, S., Stokes, W. A., Shelton, J. W., Steuer, C. E., Carlisle, J. W., Leal, T. A. B., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.07.015 · Cited by 45
Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 44
Ai, D., Hao, S., Shen, W., Wu, Q., Zhang, S., Chen, Y., Liu, Q., Deng, J., Zhu, H., Chen, K., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102471 · Cited by 48
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers
Nishizaki, D., Kurzrock, R., Miyashita, H., Adashek, J. J., Lee, S., Nikanjam, M., Eskander, R. N., Patel, H., Botta, G. P., Nesline, M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102942 · Cited by 43
Ricciuti, B., Fusco, F., Cooper, A. J., Garbo, E., Pecci, F., Aldea, M. D., Wang, X., Mayoral, M., Ginsberg, M. S., Sholl, L. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1115 · Cited by 53
Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
Schil, P. E. V., Berzenji, L., Yogeswaran, S. K., Hendriks, J. M., & Lauwers, P. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00249 · Cited by 40
Louvel, G., Bahleda, R., Ammari, S., Pechoux, C. L., Lévy, A., Massard, C., Pavec, J. L., Champiat, S., & Deutsch, É. (2018) · European Respiratory Journal · doi:10.1183/13993003.01737-2017 · Cited by 40
Vaccine and immune cell therapy in non-small cell lung cancer
Oliveres, H., Caglevic, C., Passiglia, F., Taverna, S., Smits, E., & Rolfo, C. D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.134 · Cited by 45
Hsu, P., Yang, C., Jablons, D. M., & You, L. (2018) · Biomedicines · doi:10.3390/biomedicines6040114 · Cited by 42
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
Käsmann, L., Eze, C., Taugner, J., Roengvoraphoj, O., Dantes, M., Schmidt-Hegemann, N.-S., Schiopu, S., Belka, C., & Manapov, F. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01595-3 · Cited by 44
Lung cancer in women in 21th century
Domagala-Kulawik, J. J., & Trojnar, A. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-287 · Cited by 46
Dickhoff, C., Senan, S., Schneiders, F. L., Veltman, J. D., Hashemi, S. M. S., Daniels, J. M. A., Fransen, M. F., Heineman, D. J., Radonic, T., van de Ven, P. M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07263-9 · Cited by 42
Corsini, E. M., Weissferdt, A., Pataer, A., Zhou, N., Antonoff, M. B., Hofstetter, W. L., Mehran, R. J., Rajaram, R., Rice, D. C., Roth, J. A., et al. (2020) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaa290 · Cited by 45
Hassanzadeh, C., Sita, T. L., Savoor, R., Samson, P. P., Bradley, J. D., Gentile, M. S., Roach, M. C., Mohindra, N. A., Waqar, S. N., Kruser, T. J., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1792 · Cited by 42
Buja, A., Rivera, M., Polo, A. D., Brino, E. D., Marchetti, M., Scioni, M., Pasello, G., Bortolami, A., Rebba, V. S., Schiavon, M., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13616 · Cited by 41
Therapeutic Modification of Hypoxia
Horsman, M. R., Sørensen, B. S., Busk, M., & Siemann, D. W. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.08.014 · Cited by 41
Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy
Elbanna, M., Chowdhury, N. N., Rhome, R. M., & Fishel, M. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749496 · Cited by 48
Forouzannezhad, P., Maes, D., Hippe, D. S., Thammasorn, P., Iranzad, R., Han, J., Duan, C., Liu, X., Wang, S., Chaovalitwongse, W. A., et al. (2022) · Cancers · doi:10.3390/cancers14051228 · Cited by 46
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 46
Advances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
Park, C., Oh, H., Kim, Y., Kim, Y.-H., Ahn, S., Jeong, W. G., Lee, J. Y., Lee, J. C., Choi, C., Ji, W., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.04.008 · Cited by 43
Self-citationTarin, M., Oryani, M. A., Javid, H., & Karimi‐Shahri, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114519 · Cited by 46
Exploring optimal sequencing of radiation and immunotherapy combinations
Gunderson, A. J., & Young, K. H. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.005 · Cited by 40
Immunotherapy strategy of EGFR mutant lung cancer.
Yu, S., Liu, D., Shen, B., Shi, M., & Feng, J. (2018) · Europe PMC (PubMed Central) · Cited by 42
Nesbit, E. G., Leal, T. A. B., & Kruser, T. J. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.01 · Cited by 40
Pozzessere, C., Bouchaab, H., Jumeau, R., Letovanec, I., Daccord, C., Bourhis, J., Prior, J. O., Peters, S., Lazor, R., & Beigelman‐Aubry, C. (2020) · ERJ Open Research · doi:10.1183/23120541.00165-2019 · Cited by 40
Inoue, Y., Yoshimura, K., Nishimoto, K., Inui, N., Karayama, M., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11818 · Cited by 39
Radiomics features as predictive and prognostic biomarkers in NSCLC
Bortolotto, C., Lancia, A., Stelitano, C., Montesano, M., Merizzoli, E., Agustoni, F., Stella, G. M., Preda, L., & Filippi, A. R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1852935 · Cited by 43
Sociodemographic disparities in the management of advanced lung cancer: a narrative review
Stein, J. N., Rivera, M. P., Weiner, A. A., Duma, N., Henderson, L. M., Mody, G. N., & Charlot, M. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3450 · Cited by 41
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 39
Mamdani, H. M., Schneider, B. J., Perkins, S. M., Burney, H. N., Kasi, P. M., Abushahin, L. I., Birdas, T. J., Kesler, K. A., Watkins, T. M., Badve, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736620 · Cited by 40
Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
Boustani, J., Lecoester, B., Baude, J., Latour, C., Adotévi, O., Mirjolet, C., & Truc, G. (2021) · Cancers · doi:10.3390/cancers13194893 · Cited by 51
Akhbariyoon, H., Azizpour, Y., Esfahani, M. F., Firoozabad, M. S. M., Rad, M. R., Esfahani, K. S., Khoshavi, N., Karimi, N., Shirinisaz, A., Abedi, F., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108873 · Cited by 41
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 44
Wang, S., Yuan, P., Mao, B., Li, N., Ying, J., Tao, X., Tang, W., Zhang, L., Geng, X., Zhang, F., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00244-6 · Cited by 42
Wu, F., Zhang, Z., Wang, M., Ma, Y., Verma, V., Xiao, C., Zhong, T., Chen, X., Wu, M., Yu, J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.02.005 · Cited by 41
Cucchiara, F., Petrini, I., Romei, C., Crucitta, S., Lucchesi, M., Valleggi, S., Scavone, C., Capuano, A., LIPERI, A. D., Chella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105643 · Cited by 44
Kim, S., & Lim, J. U. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-93 · Cited by 43
Radiation-induced lung injury — what do we know in the era of modern radiotherapy?
Konkol, M., Śniatała, P., & Milecki, P. (2022) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2022.0046 · Cited by 41
DNA damage and metabolic mechanisms of cancer drug resistance
Tiek, D. M., & Cheng, S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.148 · Cited by 40
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 40
Immune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma
Padilla, O. A., Minns, H. E., Wei, H.-J., Fan, W., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Gallitto, M., Yeh, R., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.219 · Cited by 42
Liquid biopsy: paving a new avenue for cancer research
Kurma, K., Eslami‐S, Z., Alix‐Panabières, C., & Cayrefourcq, L. (2024) · Cell Adhesion & Migration · doi:10.1080/19336918.2024.2395807 · Cited by 43
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.